City
Epaper

Ketamine clinics advertising false, misleading health claims: Study

By IANS | Updated: November 8, 2023 19:00 IST

New York, Nov 8 Hundreds of clinics may be using false and misleading statements in online advertising campaigns ...

Open in App

New York, Nov 8 Hundreds of clinics may be using false and misleading statements in online advertising campaigns by offering off-label and unapproved ketamine to treat a variety of mental health and pain conditions, according to researchers.

In the study published in JAMA Network Open, the researchers noted that intravenous ketamine is not approved by the US FDA to treat any mental health condition but is sometimes used off-label for it.

Oral formulations are unapproved drugs that are often advertised to produce a hallucinogenic experience at home.

"These are expensive treatments for which patients generally must pay out of pocket and the evidence base is often not robust for many of the advertised uses," said Michael DiStefano, Assistant Professor in the Department of Clinical Pharmacy at the University of Colorado Anschutz Medical Campus.

"It is important that people considering these treatments are provided with an accurate and balanced statement of the possible risks and benefits," he added.

For the study, the team identified online direct-to-consumer ketamine advertisers with at least one clinic in Maryland and a website by using six national ketamine databases.

They found 17 advertisers operating across 26 locations in Maryland that promoted infusions or ketamine assisted therapy for a wide range of conditions including depression, post-traumatic stress disorder (PTSD), anxiety and chronic pain. The advertising revealed numerous misleading representations regarding treatment and safety.

While the study focused on clinics in Maryland, DiStefano said their compilation of the six directories for ketamine treatment suggests that there are approximately 800 such clinics across the US. He said there are also several companies that will send customers oral ketamine through the mail.

"Psychedelic or hallucinogenic substances are increasingly being considered as mental health treatments. For example, Colorado is at the vanguard of developing policies to govern the use of psilocybin in depression." DiStefano said.

"It is important to be transparent and accurate when explaining the potential risks and benefits of these treatments. While these treatments can provide hope and will be effective for some patients, there are real risks associated with ketamine use, especially over the long-term. There are high financial costs to consider as well."

--IANS

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

InternationalEAM Jaishankar, Russian counterpart Lavrov to hold talks in Moscow on Aug 21

BusinessUS tariffs won’t hurt India’s growth, says S&P Global Ratings

Other SportsUP Yoddhas appoint Sumit Sangwan as captain, Ashu Singh to be vice-captain for Pro Kabaddi League season 12

MumbaiMumbai Launches ‘Smart School-Smart Block’ Programme in 217 Municipal Schools

Other SportsBWF World C'ships draw: Lakshya faces top seed Shi Yu Qi in opener; Satwik-Chirag get first round bye

International Realted Stories

InternationalPotential repercussions of China's Medog hydropower dam project enormous: Report

InternationalSalim Pistol’s arrest deals major blow to gangster-terror nexus in India

InternationalTyphoon Podul makes landfall in eastern Taiwan

InternationalIndia-Singapore Ministerial Roundtable held in Delhi, Jaishankar emphasizes synergy between government and industry

InternationalSouth Korea: Lee to visit Japan from August 23-24 for summit talks with Ishiba